liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response
Univ Manitoba, Canada.
CNRS, France; Univ Paris 05, France.
Univ Manitoba, Canada; Isfahan Univ Med Sci, Iran.
Univ Manitoba, Canada; CancerCare Manitoba, Canada.
Show others and affiliations
2018 (English)In: Pharmacology and Therapeutics, ISSN 0163-7258, E-ISSN 1879-016X, Vol. 184, p. 13-41Article, review/survey (Refereed) Published
Abstract [en]

Despite advances in neurosurgical techniques and radio-/chemotherapy, the treatment of brain tumors remains a challenge. This is particularly true for the most frequent and fatal adult brain tumor, glioblastoma (GB). Upon diagnosis, the average survival time of GB patients remains only approximately 15 months. The alkylating drug temozolomide (TMZ) is routinely used in brain tumor patients and induces apoptosis, autophagy and unfolded protein response (UPR). Here, we review these cellular mechanisms and their contributions to TMZ chemoresistance in brain tumors, with a particular emphasis on TMZ chemoresistance in glioma stem cells and GB.

Place, publisher, year, edition, pages
PERGAMON-ELSEVIER SCIENCE LTD , 2018. Vol. 184, p. 13-41
Keywords [en]
Cell death; Apoptosis; Autophagy; Unfolded protein response; Brain tumor; Glioblastoma; Glioblastoma stem cells; DNA repair; Bcl-2 family protein; Cancer therapy; Temozolomide; Alkylating drugs
National Category
Biomedical Laboratory Science/Technology
Identifiers
URN: urn:nbn:se:liu:diva-147578DOI: 10.1016/j.pharmthera.2017.10.017ISI: 000429504300002PubMedID: 29080702OAI: oai:DiVA.org:liu-147578DiVA, id: diva2:1201829
Note

Funding Agencies|Health Science Foundation [46602]; Mitacs [FR18469]; University Collaborative Research Program [47144]; Natural Sciences and Engineering Research Council of Canada (NSERC); Canada Foundation for Innovation (CFI); Cancer Research Society (CRS); Research Manitoba; Department of Surgery Research Fund

Available from: 2018-04-26 Created: 2018-04-26 Last updated: 2018-04-26

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Wiechec, Emilia
By organisation
Division of Cell BiologyFaculty of Medicine and Health Sciences
In the same journal
Pharmacology and Therapeutics
Biomedical Laboratory Science/Technology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 125 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf